IDEAYA Biosciences, Inc.

IDYA Healthcare Biotechnology

IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.

Revenue
−95.1%
EPS
−190.5%
Free cash flow
−165.9%

Quarter to September 2026, against a year earlier

30.94 0.29 +0.95%
Market cap
$3.0B
P/E
0.0×
Fwd P/E
−6.9×
Dividend yield
—
F-score
4/9
Altman Z
20.70
Beneish M
n/a
Dividend safety
n/a

IDEAYA Biosciences, Inc. (IDYA) Net margin

Alert me on Net margin

IDEAYA Biosciences, Inc.'s net margin over the twelve months to 30 September 2026 was −1,149.6%, down 1097.6 percentage points from fiscal 2025 (−52.0%). Over the past ten years it has ranged from −3,921.1% (fiscal 2024) to 0.00% (fiscal 2019); the current reading is higher than 67% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.

Net margin, annual

Embed this chart

Annual newest first

Period Net margin Change (points)
FY2025 −52.0% 3,869.11
FY2024 −3,921.1% (3,438.05)
FY2023 −483.1% (367.88)
FY2022 −115.2% 62.93
FY2021 −178.1% (1.55)
FY2020 −176.6% (176.55)
FY2019 0.00% 0.00
FY2018 0.00% 0.00
FY2017 0.00% —

Quarterly newest first

Period Net margin Change (points)
Sep 2026 −1,227.8% 41.86
Jun 2026 −1,269.6% 232.48
Mar 2026 −1,502.1% (736.46)
Dec 2025 −765.7% (823.03)
29 more quarters

Against its own ten years

Low −3,921.1% High 0.00%
Ten-year median −115.2%
Current reading's percentile 6

Net margin against peers

Company Net margin
ELVN Enliven Therapeutics, Inc. compare 0.00%
DYN Dyne Therapeutics, Inc. compare 0.00%
CELC Celcuity, Inc. compare 0.00%
BEAM Beam Therapeutics Inc. compare −73.9%
TARS Tarsus Pharmaceuticals, Inc. compare −102.9%
IDYA IDEAYA Biosciences, Inc. −1,149.6%
DNLI Denali Therapeutics Inc. compare −1,388.2%
VRDN Viridian Therapeutics, Inc. compare −1,724.1%
TLX Telix Pharmaceuticals Limited compare —
Biotechnology industry median 0.00%
Healthcare sector median 0.00%
Market median 1.06%

What Net margin is

Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.

Net Income Allotted to Shareholders ÷ Revenue

The full definition of Net margin →

More on IDYA